United Therapeutics (UTHR) Debt to Equity (2017 - 2025)
United Therapeutics (UTHR) has disclosed Debt to Equity for 14 consecutive years, with $0.03 as the latest value for Q1 2025.
- Quarterly Debt to Equity fell 73.86% to $0.03 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $0.03 through Mar 2025, down 73.86% year-over-year, with the annual reading at $0.05 for FY2024, 60.2% down from the prior year.
- Debt to Equity hit $0.03 in Q1 2025 for United Therapeutics, down from $0.05 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $0.23 in Q1 2021 to a low of $0.03 in Q1 2025.
- Historically, Debt to Equity has averaged $0.15 across 5 years, with a median of $0.16 in 2023.
- Biggest five-year swings in Debt to Equity: dropped 14.24% in 2021 and later plummeted 73.86% in 2025.
- Year by year, Debt to Equity stood at $0.2 in 2021, then decreased by 17.47% to $0.17 in 2022, then fell by 29.87% to $0.12 in 2023, then plummeted by 60.2% to $0.05 in 2024, then tumbled by 36.89% to $0.03 in 2025.
- Business Quant data shows Debt to Equity for UTHR at $0.03 in Q1 2025, $0.05 in Q4 2024, and $0.07 in Q3 2024.